Lipoprotein Lipase Activator NO-1886 Improves Fatty Liver Caused by High-Fat Feeding in Streptozotocin-Induced Diabetic Rats

Metabolism: Clinical and Experimental

Volumn 53, Issue 2, 2004, Pages 260-263

  Kusunoki, Masataka ^a   Tsutsumi, Kazuhiko ^b   Inoue, Yasuhide ^b   Hara, Tsutomu ^b   Miyata, Tetsuo ^b   Nakamura, Takao ^b   Ogawa, Hitoshi ^b   Sakakibara, Fumihiko ^b   Fukuzawa, Yoshitaka ^b   Okabayashi, Naomi ^b   Kato, Koich ^b   Ikeda, Hiroshi ^b   Kurokawa, Tsuyoshi ^b   Ishikawa, Tetsuro ^b   Otake, Kazuo ^b   Nakaya, Yutaka ^b  

^a AICHI MEDICAL UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 [(4 BROMO 2 CYANOPHENYL)CARBAMOYL]BENZYLPHOSPHONIC ACID DIETHYL ESTER; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; FATTY LIVER; GLUCOSE BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID DIET; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; TREATMENT OUTCOME;

EID: 10744220843     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2003.08.016     Document Type: Article

References (11)

1. Mayes PA: Lipid transport and storage, in Murray RK, Granner DK, Mayes PA, et al (eds): Harper's Biochemistry (ed 25). New York, NY, McGraw-Hill, 2000, pp 268-284
2. Tsutsumi K, Inoue Y, Yoshida C: Suppression of hyperlipidemia-associated cataracts in diabetic rats with the lipoprotein lipase activator NO-1886. Biol Pharmacol Bull 19:1570-1573, 1996
3. Tsutsumi K, Inoue Y, Shima A, et al: The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of HDL-cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. J Clin Invest 92:411-417, 1993
4. Tsutsumi K, Inoue Y, Sbima A, et al: Correction of hyperlriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetic rats. Diabetes 44:414-417, 1995
5. Tsutsumi K, Inoue Y, Hagi A, et al: The novel compound NO-1886 elevates plasma high-density lipoprotein cholesterol levels in hamsters and rabbits by increasing lipoprotein lipase without any effect on cholesterol ester transfer protein activity. Metabolism 46:257-260, 1997
6. Chiba T, Miura S, Sawamura F, et al: Antiatherogenic effects of a novel lipoprotein lipase-enhancing agent in cholesterol-fed New Zealand White rabbits. Arterioscler Thromb Vasc Biol 17:2601-2608, 1997
7. Junod A, Lambert AE, Stauffacher W, et al: Diabetogenic action of streptozotocin: relationship of dose to metabolic response. J Clin Invest 48:2129-2139, 1969
8. Entenman C: General procedures for separating lipid components of tissue, in Colowick SP, Kaplan NO (eds): Methods in Enzymology, vol 3. New York, NY, Academic Press, 1957, pp 299-317
9. Nakamura M, Yamada K: Studies on diabetic (KK) strain of the mouse. Diabetologia 3:212-221, 1967
10. Moller DE, David EM, Flier JS: Insulin resistance-mechanisms, syndromes and implications. N Engl J Med 325:938-948, 1991
11. Kusunoki M, Tsutsumi K, Hara T, et al: Correlation between lipid and glycogen contents in liver and insulin resistance in high-fat-fed rats treated with the lipoprotein lipase activator NO-1886. Metabolism 51:792-795, 2002